Regeneron director sells 200 shares under 10b5-1 plan

REGENERON PHARMACEUTICALS, INC. director Arthur F. Ryan reported an open-market sale of 200 shares of common stock on July 2, 2026 at a volume-weighted average price of $650.15 per share.

Rhea-AI Filing Summary

REGENERON PHARMACEUTICALS, INC. director Arthur F. Ryan reported an open-market sale of 200 shares of common stock on July 2, 2026 at a volume-weighted average price of $650.15 per share. The trade was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on October 31, 2025, indicating it was scheduled in advance. Following this transaction, Ryan directly holds 17,303 shares of Regeneron common stock.

Insights

Equity market & insider-transactions analyst

Small, pre-planned director sale that appears routine in size.

Director Arthur F. Ryan sold 200 shares of Regeneron common stock at a volume-weighted average of about $650.15 per share. The transaction is coded as an open-market sale and leaves him with 17,303 directly held shares.

The filing states the sale was made under a Rule 10b5-1(c) trading plan adopted on October 31, 2025. Such plans pre-schedule trades, reducing the informational value of the exact timing. Relative to his remaining holdings, the sale is small and looks like routine portfolio management rather than a major change in exposure.

Insider Trade Summary 10b5-1

Net Seller: 200 shares

Net Sell 1 txn

Insider RYAN ARTHUR F

Role Director

Sold 200 shs ($130K)

Type	Security	Shares	Price	Value
Sale	Common Stock	200	$650.15	$130K

Holdings After Transaction: Common Stock — 17,303 shares (Direct)

Footnotes (2)

1. F1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.
2. F2. Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price.

Key Figures

Shares sold: 200 shares Average sale price: $650.15 per share Post-transaction holdings: 17,303 shares +2 more

5 metrics

Shares sold 200 shares Open-market sale on July 2, 2026

Average sale price $650.15 per share Volume-weighted average sale price

Post-transaction holdings 17,303 shares Shares directly held after the sale

Price range $650.10–$650.19 per share Range of individual trade prices on July 2, 2026

Trading plan adoption date October 31, 2025 Rule 10b5-1(c) plan governing this sale

Key Terms

Rule 10b5-1(c), volume-weighted average price, open-market sale, Form 4

4 terms

Rule 10b5-1(c) regulatory

"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

volume-weighted average price financial

"Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19."

Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Regeneron (REGN) director Arthur F. Ryan report?

Arthur F. Ryan reported selling 200 shares of Regeneron common stock. The sale occurred on July 2, 2026 as an open-market transaction, with a volume-weighted average price of about $650.15 per share, according to the Form 4 filing data.

At what price did Arthur F. Ryan sell Regeneron (REGN) shares on July 2, 2026?

He sold Regeneron shares at a volume-weighted average price of $650.15. The filing notes actual sale prices ranged from $650.10 to $650.19 per share for the 200 shares sold in that transaction.

How many Regeneron (REGN) shares does Arthur F. Ryan hold after this Form 4 sale?

After the reported sale, Arthur F. Ryan directly holds 17,303 Regeneron common shares. This post-transaction figure in the Form 4 helps investors gauge the scale of the sale relative to his remaining ownership stake.

Was Arthur F. Ryan’s Regeneron (REGN) share sale made under a Rule 10b5-1 plan?

Yes. The filing states the disposition was made under a Rule 10b5-1(c) trading plan adopted on October 31, 2025. Such pre-arranged plans schedule trades in advance, limiting the significance of day-to-day timing decisions.

What does the volume-weighted average price disclosure mean in this Regeneron (REGN) Form 4?

The Form 4 reports a volume-weighted average sale price of $650.15 for the 200 shares. It explains that individual trades ranged from $650.10 to $650.19 and notes full pricing details are available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RYAN ARTHUR F

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN NEW YORK 10591

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2026		S(1)		200	D	$650.15(2)	17,303	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.

2. Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price.

	/s/ Arthur F. Ryan	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)